NXL Energy 3 for Keratoconus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Glaukos Investigative Site, Teaneck, NJKeratoconusNXL Energy 3 - CombinationProduct
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new treatment for keratoconus, a disease that causes the cornea to become thin and misshapen. The new treatment, called corneal cross-linking, involves using a special solution and light to strengthen the cornea.

Eligible Conditions
  • Progressive Keratoconus

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 6 Months

6 Months
Distance Uncorrected Visual Acuity (UCVA)
Topography

Trial Safety

Trial Design

5 Treatment Groups

Group 3 / Cohort 2
1 of 5
Group 4 / Cohort 2
1 of 5
Group 5 / Cohort 2
1 of 5
Group 1 / Cohort 1
1 of 5
Group 2 / Cohort 2
1 of 5

Active Control

Experimental Treatment

Non-Treatment Group

150 Total Participants · 5 Treatment Groups

Primary Treatment: NXL Energy 3 · Has Placebo Group · Phase 1 & 2

Group 1 / Cohort 1
CombinationProduct
Experimental Group · 1 Intervention: NXL Energy 3 · Intervention Types: CombinationProduct
Group 3 / Cohort 2
CombinationProduct
ActiveComparator Group · 1 Intervention: NXL Energy 1 · Intervention Types: CombinationProduct
Group 2 / Cohort 2
CombinationProduct
ShamComparator Group · 1 Intervention: Sham Treatment · Intervention Types: CombinationProduct
Group 4 / Cohort 2
CombinationProduct
ActiveComparator Group · 1 Intervention: NXL Energy 2 · Intervention Types: CombinationProduct
Group 5 / Cohort 2
CombinationProduct
ActiveComparator Group · 1 Intervention: NXL Energy 3 · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Glaukos CorporationLead Sponsor
61 Previous Clinical Trials
9,270 Total Patients Enrolled
9 Trials studying Keratoconus
1,087 Patients Enrolled for Keratoconus

Eligibility Criteria

Age 18 - 55 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Missouri100.0%
What site did they apply to?
Glaukos Investigative Site100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
Why did patients apply to this trial?
  • "I have progressive KC in both eyes treated left in 2018 and needing treatment in right after condition worsening. Ideally help can keep me from further issues and help others dealing with my illness."
How many prior treatments have patients received?
1100.0%

Frequently Asked Questions

How many participants have been accepted into this clinical experiment?

"Affirmative. According to clinicaltrials.gov, the recruitment process for this trial commenced on March 8th 2022 and was recently updated on March 29th 2022. Currently, 150 volunteers are needed at 4 distinct sites." - Anonymous Online Contributor

Unverified Answer

Is the enrollment of individuals aged 35+ being considered for this clinical trial?

"The eligibility conditions for this trial state that individuals aged between 18 and 55 are able to participate. For those under the age of 18, there are a total of 18 studies available while 35 trials exist for seniors over 65 years old." - Anonymous Online Contributor

Unverified Answer

Could I be qualified to participate in this medical trial?

"Aspiring enrollees need to meet two criteria: they must have progressive keratoconus and be aged between 18-55. This clinical trial is aiming to include a total of 150 participants." - Anonymous Online Contributor

Unverified Answer

Is this research endeavor recruiting participants at the present time?

"Clinicaltrials.gov reveals that this research project, which was first published on March 8th 2022, is actively recruiting new participants. The post has been updated as recently as March 29th of the same year." - Anonymous Online Contributor

Unverified Answer

How many distinct sites are currently hosting this investigation?

"Currently, 4 sites are running the trial. These include Boston, Dothan and Westerville as well as four other locales. To minimize traveling costs for participants, it is recommended to select the closest available medical centre." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.